OBJECTIVE: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim (18)F-FDG PET/CT after first-line treatment in patients with DLBCL. METHODS: Thirty-two patients with DLBCL underwent baseline, interim and post-treatment (18)F-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. RESULTS: Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim (18)F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival (PFS) rates were significantly different between the groups above and below SUV(max) cut-off value of 2.5 (P=0.039). No significant differences were found in the 2-year PFS rates if SUV(max) cut-off values were set as 2.0 and 3.0, respectively (P=0.360; P=0.113). CONCLUSIONS: Interim PET/CT could predict the prognosis of DLBCL patients with the SUV(max) cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion. KEY WORDS: Fludeoxyglucose F18; lymphoma; large cell; diffuse; prognosis; standard utility value.
OBJECTIVE: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. The prognostic factor currently used is not accurate enough to predict the outcomes of patients with DLBCL. The prognostic significance of interim PET/CT in DLBCL remains controversial. The aim of this study is to determine the predictive value of interim (18)F-FDG PET/CT after first-line treatment in patients with DLBCL. METHODS: Thirty-two patients with DLBCL underwent baseline, interim and post-treatment (18)F-FDG PET/CT scans. Imaging results were analyzed for the survival of patients via software SPSS 13.0, retrospectively. RESULTS: Thirty-one of the 32 patients were treated with R-CHOP regimen, and interim (18)F-FDG PET/CT of 24 patients was performed after 2 cycles of treatment. After a median follow-up period of 16.7 months, the 2-year progression-free survival (PFS) rates were significantly different between the groups above and below SUV(max) cut-off value of 2.5 (P=0.039). No significant differences were found in the 2-year PFS rates if SUV(max) cut-off values were set as 2.0 and 3.0, respectively (P=0.360; P=0.113). CONCLUSIONS: Interim PET/CT could predict the prognosis of DLBCL patients with the SUV(max) cut-off value of 2.5, but more clinical data should be concluded to confirm this conclusion. KEY WORDS: Fludeoxyglucose F18; lymphoma; large cell; diffuse; prognosis; standard utility value.
Authors: Daniele Focosi; Francesco Caracciolo; Sara Galimberti; Federico Papineschi; Mario Petrini Journal: Ann Hematol Date: 2007-12-18 Impact factor: 3.673
Authors: Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Mohren; Eva Lengfelder; Marcel Reiser; Christina Nickenig; Michael Clemens; Norma Peter; Carsten Bokemeyer; Hartmut Eimermacher; Anthony Ho; Martin Hoffmann; Roland Mertelsmann; Lorenz Trümper; Leopold Balleisen; Ruediger Liersch; Bernd Metzner; Frank Hartmann; Bertram Glass; Viola Poeschel; Norbert Schmitz; Christian Ruebe; Alfred C Feller; Markus Loeffler Journal: Lancet Oncol Date: 2008-01-15 Impact factor: 41.316
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt Journal: Nature Date: 2000-02-03 Impact factor: 49.962
Authors: Laurie H Sehn; Brian Berry; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Paul Hoskins; Richard Klasa; Kerry J Savage; Tamara Shenkier; Judy Sutherland; Randy D Gascoyne; Joseph M Connors Journal: Blood Date: 2006-11-14 Impact factor: 22.113
Authors: Z T Ying; L Mi; X J Wang; Y W Zhang; Z Yang; Y Q Song; X P Wang; W Zheng; N J Lin; M F Tu; Y Xie; L Y Ping; C Zhang; W P Liu; L J Deng; J Zhu Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2018-05-14